Daniel G. Eramian is EVP & Corporate Communications at CELL THERAPEUTICS INC (CTIC). They have made 5 open-market trades across 1 company since 2009, most recently 2012-09-20.
CIK 0001355850
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CTIC | 354,350 | $3.2M |
Shares reported on the most recent Form 4, priced at the 2012-09-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CTIC | SELL | 2012-09-20 | 2012-09-21 | $2.68 | $40K | -2.5% | +1.7% | +1.7% |
| CTIC | SELL | 2012-08-24 | 2012-08-24 | $0.39 | $37K | -2.5% | +1.7% | +1.7% |
| CTIC | SELL | 2012-06-28 | 2012-06-29 | $0.58 | $29K | -2.5% | +1.7% | +1.7% |
| CTIC | SELL | 2010-12-16 | 2010-12-17 | $0.36 | $90K | -2.5% | +1.7% | +1.7% |
| CTIC | SELL | 2009-09-25 | 2009-09-25 | $1.25 | $130K | -2.5% | +1.7% | +1.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.